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Two distinct pathways for cell death exist. Compared 10 necrotic death. physiological or apoptoticcell death is an active suicidal process that consists 
of a cascade of well-regulated synthetic events, Participation of specific genes in apoptosis. and ils possible molecular egulation. are considered 
in order to investigate the mechanism ofccii death induced by some cancer chemotherapeutic agems. 
Anticancer agent; bcf-2; Calcium; Cell cycle phase; ~34”“‘~; 53; Programmed cell death; Regulation; Sulphatcd glycoprotcin 
1. INTRODUCTION 
Apoptosis, or programmed cell death, is a major 
mechanism of maintenance of homeostasis of several 
systems of the body under physiological conditions. It 
is an integral part of embryogenesis, metamorphosis, 
organ involution, and plays a controlling role in coun- 
teracting cell proliferation [l-S]. Compared to necrotic 
death it is a relatively slower process [6,7], and involves 
a series of well-regulated synthetic events [8,9]. An apo- 
ptotic cell induces a programme so that a cascade of 
biochemical changes occur in response to the stimulus. 
The cell actively participates in the suicidal process and 
destroys itself. 
Originally described as ‘shrinkage necrosis’ [lo] apo- 
ptosis is characterised by a marked reduction in cell 
volume and an increase in buoyant density [11,121. Apo- 
ptotic bodies are characterised by their small size, dense 
chromatin, nuclear fragmentation, randomly assorted 
organelles in the cytoplasm, loss of characteristic mem- 
brane architecture and appearance of blebbing [1,7,13]. 
Significant alterations in membrane composition take 
place [2,14], 
A wide variety of physical and chemical stimuli in- 
duce apoptosis [15]. Though the exact mechanism of 
selection of the biochemical pathway of cell death is not 
fully understood it is clear that cells possess effector 
mechanisms for self-destruction, which may be acti- 
vated by several ‘relatively mild’ stimuli. In this review 
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we will briefly consider the participation of specific 
genes in the process of programmed eath in an attempt 
to elucidate the mechanism of induction of apoptosis, 
particularly by the cancer chemorherapeutic agents. 
2. BJOCHEMICAL EVENTS 
A reversible pre-commitment s ep for induction of 
genetic programming through macromolecular synthc- 
sis is essential for apoptotic death [161. Once the cascade 
of metabolic processes has been initiated within the 
committed cell it proceeds to completion [I 71. Receptors 
play a major role in perception of the stimulus. A wide 
variety of messengers and second messengers are re- 
leased. The process is mostly turned on through synthe- 
sis of macromolecules, As a final step the DNA is typi- 
cally destroyed by the action of endogenous cndonu- 
clease [18]. It is becoming evident that several genes 
participate in the cascade of events. 
2.1. Panicipaliort of speciJk genes 
Identification of the deathless mutants of Crre/~l&- 
ditis elegatrs initiated the search for the mammalian 
equivalents of the cell death (ccc/) gene. In this nematode 
a number of mutations affecting the process of cell 
death have been identified. In particular the genes ted-1, 
ted-2 and nut-1 affect apoptosis [19,20]. cccl-3 and ted-4 
genes may be involved in determining which particular 
cells express the fate of apoptosis during development 
1211 of this nematode. 
Specific expression of cell death-associated gene 
products has been reported. Originally identified as an- 
drogen repressed messages [22] in involuting rat ventral 
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prostate a group of testosterone-repressed mRNA se- 
quences have subsequently been described [23]. The 
most abundant of these sequences i  the testosterone- 
repressed prostatic message-2 (TRPM-2), the transla- 
tion product of which is a 46 kDa protein. The TRPM-2 
gene product has been identified in a variety of cell types 
undergoing apoptosis [24]. A transient but sharp rise of 
TRPM-2 mRNA has also been reported during early 
phases of regression of hormone-dependent Schionogi 
mouse mammary carcinoma [25], rat prostate [26,27], 
in androgen-independent AT3 prostatic ancer cells un- 
dergoing apoptosis following treatment with S- 
fluorodeoxyuridine and trifluorothymidine [S], during 
regression of PC82 human prostate cancer following 
androgen ablation [28], during induction of apoptosis 
of L929 tumour ceils of C3H mice upon treatment with 
recombinant human tumour necrosis factor and inhib- 
itors of DNA topoisotnerase type II [29], and also dur- 
ing death of estrogen- dependent MCF-7 human breast 
cancer cells xenografted onto nude mice [30]. Sulfated 
glycoprotein-2 (SGP-2), a constitutively expressed gene 
product originally characterised in mammalian Sertoli 
cells, has gained attention due to its rapid induction in 
numerous types of mammalian cells undergoing apo- 
ptosis, SGP-2 shares extensive sequence homology with 
TRPM-2. and it has been shown only very recently that 
both these proteins are encoded by a single gene. South- 
ern blot analysis of &/II-restricted genomic DNA 
screened for the presence of restriction fragments ho- 
mologous to SGP-2 indicated that the human homo- 
logue of SGP-2 resides on chromosome 8 [31]. 
Using the regressing rat ventral prostate gland as a 
model to study androgen-programmed cell death a se- 
ries of molecular events that accompany the process was 
characterised [32]. There is a sequential induction of 
specific gene transcripts. The first event in the cascade 
is an induction of the specific gene encoding c-fos, the 
expression of which has been linked to perturbed intra- 
cellular Ca?* levels [32]. This is followed by sequential 
induction of c-wryc and 70 kDa heat-shock protein 
mRNA [33-3.51. Simultaneous treatment of rats either 
with verapamil or with nifedipine on castration signifi- 
cantly delayed regression in both cases, indicating that 
Ca?’ flux is an early physiological step involved in the 
cascade. Furthermore the antagonists uppressed in- 
duction of transcripts encoding for both c-fos and 
TRPM-2 [33]; expression of c-H+us and pS2 also de- 
creased [30]. Recently it has been shown that an eleva- 
tion of Ca’+, 3-6-fold above the base line. induced apo- 
ptosis in androgen-independent prostatic cancer cells 
[36]. It is probable that a sustained increase in Ca” can 
play a major controlling role in activating specific genes 
needed for apoptosis. 
Wild-type ~53 protein, a product of the tumour sup- 
pressor gene, has been reported to induce apoptosis in 
the murine myeloid leukemic MI line clone, 56 [37]. 
Isolation and characterisation of a cDNA clone from 
CEM C7 cells showed homology with the human HL-14 
gene encoding a /?-galactoside-binding protein. This 
protein is over-expressed during programmed eath in- 
duced by glucocorticoids. The mouse homologue acts 
as a potent cell growth inhibitory factor [38]. Very re- 
cently Cheng et al. [39] demonstrated that tumorigen- 
icity of T leukemia Be-13 cells, which lack endogenous 
pS3 protein, can be suppressed when infected with a 
recombinant retrovirus encoding the wild-type allele of 
human pS3. Expression of pS3 reduced growth rate, 
clonogcnic potential and tumorigenicity, indicating the 
possibility of modulation of the tumorigenic phenotype 
through high-efficiency infection with retroviruses - at 
least, in leukemic ells. 
The bcl-2 protooncogene xpression enhances the 
survival of W cell precursors on withdraw1 of growth 
factors. The finding that bci-2 provides a survival ad- 
vantage for the cells [4043] by preventing the onset of 
apoptosis [44,45] suggests that, in some cells, pro- 
grammed death may bc negatively modulated by other 
genes. hcl-2 has been shown to be involved in prevention 
of apoptosis in T cells [46], thymocytes [47], germinal 
center 6 ceils and Burkitt lymphoma cells [48], and in 
pre-B leukemia lines [49]. Recent evidence suggests hat 
high levels of bcl-2 enhances cell survival under condi- 
tions of repressed c-rrt~+c expression, probably by mobil- 
isation of Ca” from mitochondria to cytoplasm. This 
in turn can activate protein kinase C and help in sur- 
vival [49,50]. Epstein-Barr virus in circulating I3 cells 
may influence suppression of apoptosis by the expres- 
sion of Epstein-Barr virus latent genes [Sl]. DNA trans- 
fection into human B cells demonstrated that expression 
of the viral membrane protein I suppresses apoptosis by 
up-regulating expression of the oncogene, bcl-2. The 
mouse anti- Fus monoclonal antibody binds to a 36 kDa 
transmembrane r ceptor which has significant homol- 
ogy with human tumour necrosis factor receptor, 
human nerve growth factor receptor and human I3 cell 
antigen, CD40. The antibody, when recognised by the 
appropriate cell surface antigen, can induce apoptosis 
either by preventing the activity ofa factor necessary for 
survival or by serving as a positive death-inducing sig 
nal [52]. 
Methylation is inhibited by the drug, T-azacytidine. 
Murine thymocyte sub-line, SAK8, reported to possess 
functional glucocorticoid receptors but resistant o 
hormone-induced eath [S3], becomes ensitive to the 
hormone treatment when treated with 5azacytidine. 
The DNA remains in a demethylated state following the 
drug treatment. and the resistance of the cell correlates 
well with the level of methylation of DNA [54], indicat- 
ing thereby that certain genes must remain in a tran- 
scriptionally activated emethylated state for glucocor- 
ticoids to be effect& 
2.2. Moleculrrr I*eggtlfrrrioll 
Little is known about molecular egulation and the 
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facto;r influencing the onset of apoptosis. Chinese ham- 
ster V79 fibroblast cells, when subjected to cold shock, 
undergo apoptotic death. Cells at the transition from 
exponential to stationary growth are the most sensitive 
[SS]. However, epidermal cells in their synthetic phase 
are reported to be more prone to damage [56]. One 
fundamental question that remains to be answered is 
whether apoptotic death can be induced at a specific 
point of the cell cycle progression. Unfortunately only 
scant information is available on this topic. While it is 
known that transcriptionally active chromatin is prefer- 
entially cleaved uring programmed eath [57] Kung et 
al. [58] reported an absence of correlation between cell 
cycle phase at the time of anticancer drug addition and 
subsequent morphology of cell death. 
IL1210 cells, when treated with cisplatin [59], and 
murine BW514 thymoma cells, when treated with dex- 
amethasone or irradiated with y-rays [BO], showed inhi- 
bition of DNA synthesis that correlated with arrest of 
the cells in the C& phase of the cell cycle. Inhibition of 
total RNA synthesis was observed initially. This was 
followed by a recovery that corresponded well with the 
passage of the cells through the G2 phase [59]. DNA 
double-strand breaks appeared in cells destined to die 
[59]. An increase in poly(ADP-ribosyl)ation is com- 
monly associated with DNA breaks [61], causing a de- 
crease in the NAD pool and in ATP levels. However, 
Sorenson et al. [59] clearly demonstrated that 
poly(ADP-ribosyl)ation occurs after DNA degradation 
as an effect of the damage. Their studies showed that 
initial suppression of DNA synthesis during S phase 
was followed by a recovery, reflecting a passage of the 
cells into Gz phase. Cells were subsequently blocked at 
the Gz phase. This arrest could not be attributed to 
detectable changes in transcription. 
A probable explanation may be given from the RAD 
9 gene function [62]. The product of this gene is essential 
for arrest of cell division following DNA damage in 
Succharon~yces cerevisiae. As postulated previously by 
Tobey 1631 RAD 9, ur its quivalent gene product, may 
be involved in the surveillance mechanism, Cells may be 
lethally damaged yet continue to progress in the cell 
Drug 
Table I 
Examples of anticancer agents reported to induce apoptosis in cultured cells 
Cell lines tested Concentration MM) Reference 
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Amsacrinc Thymocytev IQ 
Aphidicolin CHO swain AA8 I-10 
CHO strains AA8. 
uv4 I 0,2 
l-p-D-Arabinofuranosylcystosine HLGO, KG 1 A 3 :;:; 
BCNLJ CCRF/CEM C7, 
F89, Malt-4-F, EUI, 
EB2-394s 219 
Camptothecin HL60, KGIA 0.1 :::; 
Cisplutin Cl-IO strains AA& 
uv41 0.025-40 
HL60, KG 1 A 20 t;:11 
Ll210/0 2-27 1591 
Etaposide Thymocytes 50 1721 
CHO strains AAS, 
uv41 40 
HL60, KGIA 17 [;:; 
CHO 25 
Chronic lymphocytic leukemia 40 :::; 
5-Fluorodeoxyuridine CHO strains AA8, 
uv41 I 1851 
S-Fluorouracil CHO strains AA8 
uv41 IO I851 
CCRFICEM C7, 
F89, Molt-4-F, EBI, 
EB2-3945 77 F3Gl 
Methotrexate CHG strains AA8, 
uv41 0.5-128 
HL60, KG IA I t;:; 
Melphalan CCRF/CEM C7, 
F89, MOW-F, FBI, 
EB2-3945 65 
Teniposide Thymocytcs 5 ;;:; 
Vincristine Cl-10 strain AA8 0.05-O. 1 [G 
F89, Molt-4-F, EBI, 
EB2.3945 2.2 WI 
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cycle and eventually destroy themselves by apoptosis at 
the GZM phase transition [58]. Poisons of DNA topo- 
isomerase type-11 may alter the activity of specific pro- 
teins [64,65] and cause a block of cells at the G2 phase, 
Clear dissociation between drug-induced DNA topo- 
isomerasc II complexes and cytotoxicity has been re- 
ported [6S-691. Furthermore toxicity of mAMSA and 
etoposide was reduced by concomittant treatment with 
cycloheximide; but the drug-DNA topoisomerase II 
complexes were not decreased [67,70]. Fragmentation 
of internucleosomal DNA, so typical of apoptosis, has 
been reported after administration of etoposide 1713, 
teniposide and amsacrine [72]. Here DNA cleavage had 
two distinct patterns: the first cleavage was due to drug- 
topoisomerase II interactions, whereas the second 
cleavage was due to entry of the drug-treated cells into 
a phase of programmed eath [72]. It is probable that 
biochemical events that routinely occur at the G-JM 
phase transition may be involved in programmed eath 
of a cell. 
The activity of p34”“’ kinase remains inhibited uring 
the onset of apoptotic cascade following administration 
of etoposide or y-irradiation [6S], and correlates well 
with the G:, arrest of the cells. This arrest of cells at the 
Gz phase following etoposide treatment, however, is 
transient. Abnormally elevated ~34”“’ kinase activity 
was detectable during mitosis, and was related to cell 
death [73]. A prolonged mitosis, during which activities 
of specific ell cycle-regulated proteins/regulatory pro- 
teins are altered, may result in DNA damage and cell 
death. The cdc2 gene is activated and inactivated by 
specific phosphorylations and by a variety of associated 
proteins [74-761. Regulation of the gene is defined well 
in yeast: while c&25 activates the kinase [77] wrel sup- 
presses it. Cells can undergo a catastrophe when muta- 
tion causes imbalance in these genes [78]. 
DNA damage alone may not be a prerequisite for cell 
death. In human cells the ~34’~” kinase complex inter- 
acts directly with pl3 [74]. Microinjection of pl3 or 
antibodies to pl3 to rat fibroblasts causes micronuclea- 
tion and death [76]. Rung and co-workers [SS] suggested 
that cytotoxicity does not derive directly from the spe- 
cific biochemical action of the d,rug per se, but results 
from the disparate inhibition of certain cell cycle proc- 
esses or from dissociation of normally integrated and 
linked cell cycle events. In support of their hypothesis 
the authors provided examples of apoptotic death of 
Chinese hamster ovary cells treated with aphidicolin or 
vincristine. Further support of the hypothesis comes 
from the studies reporting potentiation of cytotoxicity 
of cells treated with caffeine to uncouple cell cycle 
events leading to mitosis [79-S 11, or by uncoupling pro- 
tein synthesis from DNA synthesis [82,83]. Enoch and 
Nurse [84] provided additional support. Their studies 
demonstrated that in Schkosaccharomyces pombe cdc2S 
mutants, which are defective in the control of mitosis, 
are highly susceptible to the lethal effect of DNA syn- 
thesis inhibition. Presence of an additional mutation at 
the cdcl0 gene (preventing cells from entering start) 
killed only those &Is that entered S phase prior to 
DNA syntheses inhibition. This result supports the con- 
cept that an ordered progression of cell cycle events is 
an essential prerequisite for cellular viability. 
3. HYPOTHETICAL RELEVANCE TO CANCER 
CHEMOTHERAPY 
As shown in Table I several anticancer drugs induce 
apoptosis in different cancer cells and in thymocytcs. 
This phenomenon has never been reported in cells taken 
from tumour biopsies of tumour-bearing animals or 
from cancer patirnts after drug treatment. However, the 
lack of in vivo data does not reduce the potential rele- 
vance of apoptosis for the anti-tumoral activity of the 
drug, since the cells undergoing apoptosis are probably 
rapidly destroyed by phagocytic ells, and it is their very 
short ‘half-life’ that makes it difficult to detect hem. 
It is evident hat apoptosis can be induced by a vari- 
ety of drugs with diverse chemical structure and differ- 
ent mechanism of action. Among the long list of drugs 
reported to induce apoptosis are (i) the DNA-damaging 
agents, such as BCNU, melphalan and &-platinum, 
known to cause several types of DNA damage, such as 
DNA interstrand and intrastrand crosslinks and DNA- 
protein crosslinks [88], (ii) drugs like camptothecin that 
cause protein.associated DNA strand breaks mediated 
by the enzyme DNA topoisomerase I, (iii) the epipodo- 
phyllotoxins and intercalating agents that are poisons 
of DNA topoisomerase II, (iv) inhibitors of mitotic 
spindle apparatus, uch as the vinca alkaloids, (v) inhib- 
itors of DNA synthesis (aphidicolin), and (vi) several 
antimetabolites. 
The fact that apoptosis can be induced by perturbing 
cell biochemistry with a variety of antineoplastic drugs 
suggests that the phenomenon can be triggered by mul- 
tiple mechanisms, orthat it occurs via a common mech- 
anism which is activated by all these drugs. All these 
drugs cause a block of macromolecule synthesis and of 
the progression of the celi cycle, which is reported to 
occur before the cytotoxicity is evident. The various 
drugs listed in Table I can block the cells at different 
points of the cell cycle: while some block the cells at the 
beginning of the S phase, others block in G1, while some 
other drugs induce a block in mitosis [63]. It seems 
unlikely, therefore, that the activation of apoptosis is 
mediated by a specific block in the cell cycle. More 
probably it appears to be related to a general metabolic 
stress and/or damage of cell structure(s). Unfortunately 
the steps ieading to endonuclease activation following 
perception of the death signal are still very poorly eluci- 
dated. 
As previously indicated a number of genes involved 
in the apoptotic process have already been identified. 
125 
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Biochemical characterisation f the function of the gene 
products will allow the investigation of the mechanism 
of drug-induced apoptosis. It appears that the majority 
of cells, neoplastic or otherwise. in which the phenome- 
non of drug-induced apoptosis has been described, are 
derived from the haemopoietic system. It is unclear 
whether the lack of data on drug-induced apoptosis in 
cells derived from solid tumours is due to paucity of 
studies or to the fact that negative data are generally too 
difficult to publish. It seems possible that the phenome- 
non of apoptosis is phenotypically determined and can 
be induced only in some cell types. It may be that the 
drugs can induce or enhance the biochemical pathways 
leading to apoptotic death only in the cells where the 
phenomenon can occur naturally under certain physio- 
logical conditions, It seems tempting to speculate that 
turnout-s that respond to chemotherapy (e.g. some leu- 
kemia, lymphoma and embryonal carcinomas) are 
those derived from tissues already ‘predisposed’ to ap- 
optotic death. Here the drugs probably work by simu- 
lating a stimulus which normally activates the suicidal 
programme. Experimental studies aimed at comparison 
of induction of apoptosis by cancer chemotherapeutic 
agents in neoplastic and normal cells of different origin 
are warranted to elucidate this point. 
4. CONCLUSIONS 
In this paper we have critically reviewed the most 
relevant available literature on the biochemical events 
and molecular regulation of apoptosis. We have also 
discussed the possibility that this phenomenon could be 
relevant for the susceptibility of the tumours to the- 
motherapeutic agents. This hypothesis is still specula- 
tive at the moment, but the availability of a better 
knowledge of the molecular events involved in the apop 
totic process makes it realistic to investigate the mecha- 
nisms involved in the induction of programmed eath 
by anticancer drugs. 
It is still unclear if all cells can undergo apoptosis 
under certain circumstances or whether it is a character- 
istic of only some tissues which are under the regulation 
of specific hormone or growth factors, An important 
issue, which has not been discussed here, concerns the 
choice of the most suitable method for the evaluation 
of the phenomenon. This issue is of potential relevance 
when the process of apoptosis is evaluated after expos- 
ing the cells to chemicals that can cause necrosis or 
apoptosis, depending on the intensity or severity of the 
stimulus. Only a very fine line separates the two intensi- 
ties producing apoptosis and necrosis. Therefore a reli- 
able quantitative measure of the two types of death over 
time is needed. 
As indicated in this review there are reasons to believe 
that the mechanism of programmed cell death is regu- 
lated by a definite action of genes. It may be possible 
that the modulation of the gene in a coordinated fashion 
126 
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will result, advantageously, in the selection of cell killing 
by antineoplastic agents specifically against tumoral 
cells [89]. Although this hypothesis is still entirely spec- 
ulative it indicates a radically novel approach for the 
identification of new effective anticancer therapies. 
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